Tenax Therapeutics (TENX) Restructuring Costs (2012 - 2013)

Tenax Therapeutics (TENX) posted quarterly Restructuring Costs of $2941.0 for Q1 2013, down 98.27% on a QoQ basis from $170298.0 in Q4 2012.

Tenax Therapeutics (TENX) Restructuring Costs (2012 - 2013) Analysis & Trends

Tenax Therapeutics has reported Restructuring Costs for 2 years, with the latest figure at $2941.0 in Q1 2013.

Restructuring Costs for Q1 2013 came in at $2941.0, changed N/A year-over-year; the trailing twelve-month figure through Apr 2013 was $220715.0 (changed N/A YoY), and the FY2013 annual result was $220715.0, changed N/A from the prior year.
Restructuring Costs slipped to $2941.0 in Q1 2013, from $170298.0 in the prior quarter.
Over five years, Restructuring Costs peaked at $170298.0 in Q4 2012 and troughed at $2941.0 in Q1 2013.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Tenax Therapeutics	80.73 Mn	80.73 Mn	-

Download Data